StemCells Inc (STEM) was Downgraded by Maxim Group to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Maxim Group advised their investors in a research report released on May 31, 2016.
Many Wall Street Analysts have commented on StemCells Inc. Rodman & Renshaw Resumed StemCells Inc on Apr 20, 2016 to “Buy”, Price Target of the shares are set at $1.50.Shares were Reiterated by Chardan Capital Markets on Mar 28, 2016 to “Buy” and Lowered the Price Target to $ 0.50 from a previous price target of $1 .
StemCells Inc opened for trading at $3 and hit $3.05 on the upside on Friday, eventually ending the session at $3.03, with a gain of 2.02% or 0.06 points. The heightened volatility saw the trading volume jump to 92,272 shares. Company has a market cap of $35 M.
In a different news, on Apr 18, 2016, Gregory T Schiffman (CFO) purchased 166,000 shares at $0.30 per share price. According to the SEC, on Dec 30, 2015, Kenneth Blair Stratton (General Counsel) sold 104,549 shares at $0.45 per share price.
StemCells Inc. is engaged in the research development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. The Company’s lead product development program is its CNS Program in which it is developing applications for HuCNS-SC cells its human neural platform technology. It is in clinical development with its HuCNS-SC cells for a range of diseases and disorders of the central nervous system. The CNS consists of the brain spinal cord and eye and it is stem cell company in clinical development for indications in all three compartments comprising the CNS which include with respect to the brain with respect to the spinal cord and with respect to the eye. The Phase I clinical trial was completed in Pelizeaus-Merzbacher Disease Neuronal Ceroid Lipofuscinosis and Phase I/II clinical trial in multiple sites for chronic spinal cord injury was completed.